Evidence map›Paper›PMID 40596141›Full record

ArticleScientific reports2025

Optimizing nanomaterial dosages in concrete for structural applications using experimental design techniques.

Ratchagaraja Dhairiyasamy, Deepika Gabiriel, Deekshant Varshney, Subhav Singh

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ratchagaraja DhairiyasamySaveetha School of Engineering, Department of Electronics and Communication Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Deepika GabirielCollege of Engineering and Technology, Aksum University, Aksum, Ethiopia. gabirieldee@gmail.com.
Deekshant VarshneyCentre of Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140417, Punjab, India.
Subhav SinghChitkara Centre for Research and Development, Chitkara University, Shimla, 174103, Himachal Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterial-enhanced concrete offers a transformative route to improve mechanical and durability performance for structural applications. Despite the promise of nano-silica (NS), nano-alumina (NA), and graphene oxide (GO), a comparative evaluation under unified conditions remains limited. This study addresses that gap by experimentally investigating the effects of NS (1-3%), NA (1-3%), and GO (0.05-0.15%) on workability, strength, and durability properties of concrete. A two-factor statistical optimization using Response Surface Methodology (RSM) was employed to model and predict compressive, tensile, and flexural strengths as functions of nanomaterial and superplasticizer dosages. Experimental results showed that NS and GO achieved a ~ 25% increase in compressive strength, while GO yielded the highest flexural improvement (~ 40%) at only 0.10% dosage. Durability metrics such as RCPT charge passed, water absorption, and sulfate resistance were significantly enhanced across all nano-modified mixes, with NS and GO outperforming NA. RSM confirmed nanomaterial dosage as the dominant factor influencing strength, while superplasticizer had no statistically significant effect. Optimal dosages were identified for each nanomaterial to maximize performance while avoiding overdosing effects. This study provides a comprehensive, optimization-driven comparison of NS, NA, and GO in concrete, offering valuable insights for designing durable, high-performance cementitious systems using tailored nanomodification strategies.

Indexed as

ConcreteDurabilityGraphene oxideMechanical propertiesMicrostructureNano-aluminaNano-silica

Identifiers

PMID40596141
PMCPMC12219607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.